Premium
Napsin A is a useful marker for metastatic adenocarcinomas of pulmonary origin
Author(s) -
Kim MoonYoung,
Go Heounjeong,
Koh Jaemoon,
Lee Kyoungbun,
Min HyeSook,
Kim MinA,
Jeon Yoon Kyung,
Lee HyeSeung,
Moon KyungChul,
Park So Yeon,
Kim WooHo,
Chung Doo Hyun
Publication year - 2014
Publication title -
histopathology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.626
H-Index - 124
eISSN - 1365-2559
pISSN - 0309-0167
DOI - 10.1111/his.12383
Subject(s) - pulmonary adenocarcinoma , adenocarcinoma , pathology , medicine , lung , immunohistochemistry , ovary , tissue microarray , carcinoma , metastatic carcinoma , cancer
Aims To address whether napsin A is useful for identifying metastatic adenocarcinomas of pulmonary origin. Methods and results Fifty‐four cases of adenocarcinoma that metastasized from the lungs to various sites and 1762 cases of carcinoma from various organs were immunostained for napsin A , TTF ‐1, CK 7, CK 20 and CDX 2 using tissue microarray. The expression patterns of napsin A and TTF ‐1 in metastatic pulmonary adenocarcinomas were compared with matched primary lung tumours. Napsin A and TTF ‐1 were expressed in 87.0% and 81.5% of the metastatic pulmonary adenocarcinomas, respectively. Although there was no significant difference in the positivity of napsin A and TTF ‐1 as a single marker in metastatic pulmonary adenocarcinomas, the expression scores for napsin A were much higher than those for TTF ‐1 ( P < 0.001). Moreover, the positivity and expression scores of napsin A in primary pulmonary adenocarcinomas were maintained in metastatic adenocarcinomas better than TTF ‐1. Most non‐pulmonary adenocarcinomas were negative for napsin A , except for renal cell carcinomas (13.4%), ovarian adenocarcinomas (7.1%) and uterine endometrial adenocarcinomas (14.5%). In particular, clear cell adenocarcinomas of ovary (68.8%) and uterus (66.7%) frequently expressed napsin A . Conclusions These data suggest that napsin A may be a useful marker for identifying metastatic adenocarcinomas of pulmonary origin in combination with TTF ‐1.